Drugs associated with drug-induced interstitial lung diseases
Open Access
- 13 August 2021
- journal article
- Published by Publishing House OKI in Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice
- No. 2,p. 39-51
- https://doi.org/10.37489/2588-0519-2021-2-39-51
Abstract
Interstitial lesion is one of the causes of respiratory failure. Drugs are a modifiable etiological factor of lung damage. Medications most commonly associated with drug-induced interstitial lung disease include antineoplastic drugs, disease-modifying anti-rheumatic drugs and amiodarone. According to the latest literature data, the previously described link between anti-rheumatic drugs and interstitial lung diseases is very inconsistent. It may even be a protective effect of this group of drugs on the lung tissue. The relationship between statin use and interstitial lesions is also complex and not fully understood. It is necessary to carefully assess the appearance of respiratory tract complaints in patients taking statins as in other groups of patients. Prescription of additional diagnostic methods is necessary to close monitoring and prevention the toxic effect of these drugs. These actions, as well as the potential prescription of steroid therapy and change in the underlying disease treatment approaches, are an important factor in reducing the incidence of respiratory failure in the population.Keywords
This publication has 98 references indexed in Scilit:
- Gemcitabine Plus Erlotinib for Advanced Pancreatic Cancer: A Systematic Review with Meta-AnalysisPLOS ONE, 2013
- Incidence and management of mTOR inhibitor-associated pneumonitis in patients with metastatic renal cell carcinomaAnnals of Oncology, 2012
- Non-infectious pulmonary complications of newer biological agents for rheumatic diseases--a systematic literature reviewRheumatology, 2011
- Pneumonitis associated with sirolimus: clinical characteristics, risk factors and outcome a single-centre experience and review of the literatureNephrology Dialysis Transplantation, 2007
- Rituximab‐induced interstitial lung diseaseAmerican Journal of Hematology, 2007
- Characterisation of the lung toxicity of the cell cycle inhibitor temsirolimusEuropean Journal of Cancer, 2006
- Potential therapeutic role for statins in respiratory diseaseThorax, 2006
- Un cas de pneumopathie interstitielle rapporté sous atorvastatine (Tahor®) : synthèse des cas publiés sous statinesTherapies, 2006
- Severe acute interstitial pnuemonia and gefitinibLung Cancer, 2004
- Prediction of BCNU Pulmonary Toxicity in Patients with Malignant GliomasThe New England Journal of Medicine, 1980